Global AD

Collapse

Announcement

Collapse
No announcement yet.

Safety of dupilumab in patients with atopic dermatitis. Expert opinion

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Safety of dupilumab in patients with atopic dermatitis. Expert opinion

    Dupilumab, the first biologic drug to be approved for the treatment of moderate to severe atopic dermatitis in adolescents and adults, has shown efficacy and safety in clinical trials. Data on long-term safety is limited but crucial for pharmacovigilance. Therefore, we performed this review to evaluate available real-world data on the long-term safety of dupilumab in atopic dermatitis.Areas covered: PubMed and Google Scholar databases were searched for randomized controlled clinical trials...

    More...
Working...
X